Form 8-K - Current report:
SEC Accession No. 0001140361-25-006302
Filing Date
2025-02-27
Accepted
2025-02-27 16:48:19
Documents
15
Period of Report
2025-02-27
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ef20044486_8k.htm   iXBRL 8-K 29995
2 EXHIBIT 99.1 ef20044486_ex99-1.htm EX-99.1 108841
6 image00002.jpg GRAPHIC 4401
  Complete submission text file 0001140361-25-006302.txt   292605

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA rckt-20250227.xsd EX-101.SCH 3994
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE rckt-20250227_lab.xml EX-101.LAB 21966
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rckt-20250227_pre.xml EX-101.PRE 16052
17 EXTRACTED XBRL INSTANCE DOCUMENT ef20044486_8k_htm.xml XML 4057
Mailing Address 350 FIFTH AVENUE SUITE 7530 NEW YORK NY 10118
Business Address 350 FIFTH AVENUE SUITE 7530 NEW YORK NY 10118 646-440-9100
ROCKET PHARMACEUTICALS, INC. (Filer) CIK: 0001281895 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36829 | Film No.: 25680199
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)